Skip to main content
. Author manuscript; available in PMC: 2014 Jul 28.
Published in final edited form as: Cancer Lett. 2013 Mar 7;335(2):404–411. doi: 10.1016/j.canlet.2013.02.059

Table 1.

Drug sensitivity of BCap37, Bads-200 and Bats-72

Drug BCap37
Bads-200
Bats-72
IC50 * (nM) IC50 (nM) RI** IC50 (nM) RI
Paclitaxel 4 ± 1.2 4550 ± 340 1138 454 ± 65 113.5
Docetaxel 2.7 ± 0.4 1680 ± 80 622.2 248 ± 38 91.9
Vinorelbine 20 ± 3.4 1850 ± 160 92.5 1040 ± 180 52
Doxorubicin 270 ± 26 9950 ± 650 36.9 5600 ± 240 20.7
Etoposide 12300 ± 800 79000 ± 5200 6.4 59100 ± 3300 4.8
Gemcitabine 418 ± 36 482 ± 63 1.2 1400 ± 90 3.4
Methotrexate 18.6 ± 3.9 19.6 ± 7.4 1.1 39.5 ± 5.8 2.12
5-flourouracil 15200 ± 1200 22400 ± 1800 1.5 25800 ± 2300 1.7
Cisplatin 1550 ± 240 1220 ± 210 0.79 1500 ± 170 0.97
*

The IC50 values were defined as the concentration of cells inhibiting growth at 50%.

**

Drug resistance index (RI) was determined by deviding IC50 values of Bads-200 or Bats-72 by that of BCap37 cells.